CN102793734A - Novel medicament for treating cardio-cerebrovascular diseases and preparation method - Google Patents
Novel medicament for treating cardio-cerebrovascular diseases and preparation method Download PDFInfo
- Publication number
- CN102793734A CN102793734A CN2012103181993A CN201210318199A CN102793734A CN 102793734 A CN102793734 A CN 102793734A CN 2012103181993 A CN2012103181993 A CN 2012103181993A CN 201210318199 A CN201210318199 A CN 201210318199A CN 102793734 A CN102793734 A CN 102793734A
- Authority
- CN
- China
- Prior art keywords
- powder
- hirudo
- parts
- pheretima
- radix notoginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a novel medicament for treating the cardio-cerebrovascular diseases and a preparation method and belongs to the technical field of preparation of the novel medicament for treating the cardio-cerebrovascular diseases. According to the invention, blood-sucking leeches, panax pseudoginseng and earthworm are used as raw materials. According to the invention, by a special preparation process of carrying out liquid nitrogen flash freezing, low-temperature superfine grinding and freeze drying before sterilization on the raw materials, the grinding fineness can reach 1 to 10 micrometers, the active ingredients of the blood-sucking leeches can be stored to the greatest extent, the active ingredients can be sufficiently adsorbed by a patient, and the novel medicament has comprehensive effects of promoting circulation, removing stasis, resisting to coagulation, reducing the pressure, lowering lipid, resisting to platelet aggregation and dissolving thrombi and is safe and reliable to take. The invention solves the problems that an existing medicament which uses leeches as the raw materials and is used for treating the cardio-cerebrovascular diseases adopts non blood-sucking leeches as the medicine and adopts a conventional grinding method, so that the antithrombase effect is poor and the curative effect is influenced; and enteric capsules only adopt the single medicine of blood-sucking leech and have poor effects of reducing the pressure, lowering the lipid and dissolving the thrombi and the preparation process ensures the active ingredients of the leeches not to be completely stored and is unbeneficial for a patient to adsorb the active ingredients.
Description
Technical field
The present invention relates to a kind of new drug and method for preparing of treating cardiovascular and cerebrovascular disease, belong to the cardiovascular and cerebrovascular diseases medicament preparing technical field.
Background technology
Cardiovascular and cerebrovascular disease has the characteristics of " sickness rate is high, disability rate is high, mortality rate is high, relapse rate is high, and complication is many ", has become the healthy No.1 killer of almost all people that current social serious threat comprises youngster.Hyperlipemia, blood are sticky, atherosclerosis, hypertension etc. are the arch-criminals who causes cardiovascular and cerebrovascular disease.At present, the medicine of treatment cardiovascular and cerebrovascular disease is more, but the Western medicine side effect is big, and Chinese medicine adopts traditional handicraft to process more, and effective ingredient can not guarantee.
Hirudo has another name called Hirudo, is the good medicine of blood circulation promoting and blood stasis dispelling.Modern medicine study shows that the contained hirudin of Hirudo is the strongest natural inhibitor to thrombin in the known anticoagulative substance of being found in the world up to now.Hirudin has very significant blood vessel dilating, blood viscosity lowering, the sanguimotor effect of increase; With existing only in the medicament that the hirudin in the Hirudo body is made into, diseases such as hypertension, apoplexy, coronary heart disease, arterial thrombus there is certain therapeutic effect.
It at present is not following tens kinds of the medicine of raw material for treating cardiovascular and cerebrovascular disease with the Hirudo; But except that the Maixuekang enteric capsule, other drug adopts all not that Hirudo is used as medicine, because Hirudo does not contain natural hirudin; Therefore the effect of antithrombase is poor, has a strong impact on therapeutic effect.And the Maixuekang capsule is the folk prescription medicine that only adopts Hirudo, and the effect of its antithrombase is fairly obvious, but the effect of its blood pressure lowering, blood fat reducing and thrombus dissolving is relatively poor relatively.In addition; Except that being rich in hirudin, also contain hyaluronidase, vasodilatin, prostaglandin isoreactivity material in the Hirudo body; And the necessary aminoacid of human body; But its processing technology of Chinese patent medicine of the cardiovascular and cerebrovascular disease of Hirudo class treatment at present all can not be preserved many active component of Hirudo fully, is unfavorable for that the patient absorbs, and influences therapeutic effect.
Summary of the invention
The objective of the invention is to; Providing a kind of is raw material with Hirudo, Radix Notoginseng, Pheretima, processes through special preparation technology, can preserve the active component of Hirudo to greatest extent; Be beneficial to absorption; Good effect has blood circulation promoting and blood stasis dispelling, the resultant effect of anticoagulant, blood pressure lowering, blood fat reducing, antiplatelet aggregation, thrombolytic.Solve existing be the medicine of the raw material for treating cardiovascular and cerebrovascular disease weak effect that adopts Hirudo not to be used as medicine to make antithrombase with the Hirudo, affect the treatment; And enteric coated capsule only adopts Hirudo folk prescription medicine, and blood pressure lowering, blood fat reducing and thrombolytic effect are relatively poor; And the existing preparation technology of Hirudo pharmacy that adopts all can not preserve many active component of Hirudo fully, is unfavorable for that the patient absorbs the new drug and the method for preparing of the treatment cardiovascular and cerebrovascular disease of problem.
The present invention realizes above-mentioned purpose through following technical scheme:
A kind of new drug of treating cardiovascular and cerebrovascular disease is characterized in that, it is processed by the raw material of following weight parts:
8～12 parts of Hirudo powder, 8～12 parts of Radix Notoginseng powder, 5～8 parts of Pheretima powder.
Described Hirudo powder is blood-eating hirudo powder, beautiful doctor trematodiasis powder, Hirudinaria manillensis powder, excellent stricture of vagina cattle trematodiasis powder, Hubei cattle trematodiasis powder or Nanjing cattle trematodiasis powder.
Preferred version of the present invention is:
9～11 parts of Hirudo powder, 9～11 parts of Radix Notoginseng powder, 6～7 parts of Pheretima powder.
Preferred plan of the present invention is:
10 parts of Hirudo powder, 10 parts of Radix Notoginseng powder, 7 parts of Pheretima powder.
The present invention is based on motherland's Chinese medicine to pathogenetic research of cardiovascular and cerebrovascular disease and Therapeutic Principle; Scientific achievement with reference to the modern Chinese medicine theoretical research; By the theory of Chinese medical science prescription; The medication that breaks traditions taboo adopts Hirudo powder, Radix Notoginseng, Pheretima three flavor medical materials to form compound recipe, reaches the resultant effect of anticoagulant, blood pressure lowering, expander, thrombolytic.And through special preparation technology; Hirudo, Pheretima, three kinds of medical materials of Radix Notoginseng are carried out liquid nitrogen flash freezer, micronizing, lyophilization processing; Preserved the effective ingredient of Hirudo, Radix Notoginseng and Pheretima to greatest extent; Can make that contained effective ingredient lets patient fully absorb in the medicament, improve therapeutic effect greatly; And the effect of antithrombase, blood pressure lowering, blood fat reducing and thrombus dissolving is fairly obvious, reaches the good result to the cardiovascular and cerebrovascular disease treating both the principal and secondary aspects of a disease.
In the above-mentioned material component of the present invention, the property feature and the effect of every component crude drug are following:
Hirudo: effect with blood circulation promoting and blood stasis dispelling.Modern medicine study shows that the contained hirudin of Hirudo is the strongest natural inhibitor to thrombin in the known anticoagulative substance of being found in the world up to now.Hirudin also has very significant blood vessel dilating, blood viscosity lowering, the sanguimotor effect of increase; Hirudin with existing only in the Hirudo body is made into medicament, and diseases such as hypertension, apoplexy, coronary heart disease, arterial thrombus are had better therapeutic effect.Hirudo also contains hyaluronidase, vasodilatin, prostaglandin isoreactivity material except that being rich in hirudin, and all human body essential amino acids.
Radix Notoginseng: have the dissipating blood stasis hemostasis, the effect of subduing swelling and relieving pain.The main effective ingredient of Radix Notoginseng is a Radix Notoginseng total arasaponins.Experiment shows that Radix Notoginseng total arasaponins has obvious antiplatelet aggregation, suppresses the effect of platelet adhesion, and antithrombotic forms, microcirculation improvement.Can significantly reduce hyperpietic MDA, obviously increased SOD can reverse angina of effort patient's left chamber diastolic dysfunction, even can make it to recover normal.The cerebral infarction acute stage, there is clinical therapeutic efficacy preferably, can significantly improves GBI or the focal ischemia cerebral edema between flush phase again.
Pheretima: contain lumbrifebrine, Lumbrukinase etc.Lumbrukinase has been proved to be has clinical value preferably, and Lumbrukinase and thrombosis are that fibrin has special affinity, can effectively dissolve little bolt; Microcirculation improvement increases blood vessel elasticity, improves blood vessel oxygen supply function; Blood viscosity lowering reduces platelet aggregation rate, suppresses thrombosis and forms once more.
A kind of method for preparing that is used for the new drug of above-mentioned treatment cardiovascular and cerebrovascular disease is characterized in that, it is made up of following step:
The first step, selection check medical material:
Hirudo: must be that healthy live body or live body freezes article, antithrombin activity component content＞50A-TU/g, content of beary metal should satisfy the pharmacopeia requirement, total ash≤5.0%, acid-insoluble ash≤2.0%, extractum＞2.0%.
Radix Notoginseng: select root and the supporting root of Radix Notoginseng for use, its total moisture≤14.0%, total ash≤6.0%, acid-insoluble ash≤3.0%, ethanol-soluble extractives＞16.0%, Radix Notoginseng total arasaponins＞5.0%.
Pheretima: select LUMBRICUS or thin white silk used in ancient China Pheretima, require its total moisture≤12.0%, total ash≤10.0%, acid-insoluble ash≤5.0%, heavy metal≤1,000,000/30, extractum＞16.0%.
Second step, medical material are handled:
The live body Hirudo is cleaned up with clear water, and the Pheretima live body then will be cut clean earth open, and the official method detection level is pressed in the sampling of Hirudo, Pheretima and three kinds of raw materials of Radix Notoginseng, and it is for use to detect qualified back.
The 3rd step, cryotherapy:
Hirudo and Pheretima are put into refrigerated cylinder, the amount of putting into≤refrigerated cylinder volume half the, inwards charges into liquid nitrogen again, liquid nitrogen reaches four of refrigerated cylinder volume/three o'clock to be stopped to charge into, and keeps 20 minutes, treat Hirudo and Pheretima adfreezing after taking-up for use.
The 4th step, pulverizing:
Hirudo, Pheretima and the Radix Notoginseng dry product that will pass through the liquid nitrogen quick freezing are respectively charged in the super micron mill of band refrigerating plant, pulverize temperature and are controlled at below 4 ℃, are crushed to 1～10 micron, and it is for use to pulverize back collection powder.
The 5th step, lyophilization:
Above-mentioned three kinds of powder are respectively charged into the freezer dryer lyophilizing, detect moisture＜10% back of three kinds of powder and take out.
The 6th step, mixing:
Take by weighing mixing behind each raw material by above-mentioned parts by weight of raw materials.
The 7th step, sterilization:
Powder behind the 6th step mixing was shone 1 minute under the Co60 ray; Perhaps the powder behind the mixing is packed in the band agitating device rustless steel container that can seal; Half of powder charge weight≤rustless steel container volume; In rustless steel container, charge into the ozone gas of 20000～33000ppm again, stir, be full of the back sealing and stirred 30 minutes while filling; Collect powder then, packing warehouse-in, room temperature preservation.
The 8th step, making finished product:
Powder after the sterilization is processed capsule formulation or tablet form finished product by following mode;
Capsule formulation: the powder after the sterilization of the 7th step is incapsulated in the make-up machine, and capsule employing capacity is No. 1 capsule of 0.25 gram, and every net weight 0.25 gram after packing into is chosen the product of breakage, is made into capsule board or bottled product then.
Tablet: the medical starch of making the requirement adding ormal weight of tablet by the pharmaceutical factory through sterilization; Tabletting, sugar coating, every weight 1g～2g, every gram contain above-mentioned powder 0.25g.
The 9th step, packing back warehouse-in, room temperature preservation.
The present invention's beneficial effect compared with prior art is:
1, the new drug of this treatment cardiovascular and cerebrovascular disease and method for preparing are raw material with Hirudo, Radix Notoginseng, Pheretima etc.; Chinese medicine preparation technology through special processes oral new medicament; The compound effect that three kinds of medical materials are used as medicine jointly is superior to existing enteric coated capsule folk prescription, and therapeutic effect is superior to Hirudo and Folium Salicis Babylonicae Hirudo, and definite ingredients; Pharmacology is clear, takes safe and reliable.
2, new drug and method for preparing of this treatment cardiovascular and cerebrovascular disease adopt advanced liquid nitrogen flash freezer method to handle medical material, have preserved the effective ingredient of Hirudo and Pheretima medical material to greatest extent, have solved Hirudo, this type of Pheretima animal tissue can not be by the difficult problem of micronizing.
3, the new drug of this treatment cardiovascular and cerebrovascular disease and method for preparing adopt micronizing to handle medical material, and the animal tissue of Hirudo and Pheretima and the effective ingredient of Radix Notoginseng plant tissue are discharged fully, more help the patient and absorb, and have strengthened curative effect greatly.
4, the new drug of this treatment cardiovascular and cerebrovascular disease and method for preparing are carried out the lyophilization processing to Leech, Earthworm and Notoginseng Root; Solved the problem of effective ingredient easy devitalization in dry run of Chinese crude drug; Preserve the effective ingredient of medical material to greatest extent, further improved therapeutic effect.
The specific embodiment
Through concrete embodiment the new drug and the method for preparing of this treatment cardiovascular and cerebrovascular disease further are described below below:
The new drug of this treatment cardiovascular and cerebrovascular disease is earlier medical material Hirudo, Radix Notoginseng, Pheretima to be clayed into power respectively, makes by the percentage by weight mixing of following component again.Described Hirudo is a kind of in blood-eating hirudo (Hirudo nipponia Whitman), beautiful doctor trematodiasis (Hirudo pulchra Song), Hirudinaria manillensis (Poecilobdella manllillensis), excellent stricture of vagina cattle trematodiasis (Poecilobdella javanica), Hubei cattle trematodiasis (Poecilobdella hubeiensis Yang) or the Nanjing cattle trematodiasis (Poecilobdella nanjingensis sp.nov.).
The percentage by weight of component is 8～12 parts of Hirudo powder, 8～12 parts of Radix Notoginseng powder, 5～8 parts of Pheretima powder.In order to reach best effects, preferred version of the present invention is 9～11 parts of Hirudo powder, 9～11 parts of Radix Notoginseng powder, 6～7 parts of Pheretima powder.Preferred plan is 10 parts of Hirudo powder, 10 parts of Radix Notoginseng powder, 7 parts of Pheretima powder.
The method for preparing of the new drug of above-mentioned treatment cardiovascular and cerebrovascular disease is made up of following step:
The first step, selection check medical material:
Hirudo: must be that healthy live body or live body freezes article, antithrombin activity composition (hirudin) content＞50A-TU/g, content of beary metal should satisfy the pharmacopeia requirement, total ash≤5.0%, acid-insoluble ash≤2.0%, extractum＞2.0%.Hirudo is selected a kind of in blood-eating hirudo (Hirudo nipponia Whitman), beautiful doctor trematodiasis (Hirudo pulchra Song), Hirudinaria manillensis (Poecilobdella manllillensis), excellent stricture of vagina cattle trematodiasis (Poecilobdella javanica), Hubei cattle trematodiasis (Poecilobdella hubeiensis Yang), the Nanjing cattle trematodiasis (Poecilobdella nanjingensis sp.nov.) for use.
Radix Notoginseng: select root and the supporting root of Radix Notoginseng for use, require its total moisture≤14.0%, total ash≤6.0%, acid-insoluble ash≤3.0%, ethanol-soluble extractives＞16.0%.Radix Notoginseng total arasaponins＞5.0%.
Pheretima: select LUMBRICUS or thin white silk used in ancient China Pheretima, require its total moisture≤12.0%, total ash≤10.0%, acid-insoluble ash≤5.0%, heavy metal≤1,000,000/30, extractum＞16.0%.
Second step, medical material are handled:
The live body Hirudo is cleaned up with clear water, and the Pheretima live body then will be cut clean earth open.The official method detection level is pressed in the sampling of Hirudo, Pheretima and three kinds of raw materials of Radix Notoginseng, detects qualified back and places for use.
The 3rd step, cryotherapy:
Hirudo and Pheretima are put into refrigerated cylinder, the amount of putting into≤refrigerated cylinder volume half the, inwards charges into liquid nitrogen again, liquid nitrogen reaches four of refrigerated cylinder volume/three o'clock to be stopped to charge into, and keeps 20 minutes, treat Hirudo and Pheretima adfreezing after taking-up for use.
The 4th step, pulverizing:
Hirudo, Pheretima and the Radix Notoginseng dry product that will pass through the liquid nitrogen quick freezing are respectively charged in the super micron mill of band refrigerating plant, pulverize temperature and are controlled at below 4 ℃, are crushed to 1～10 micron, and it is for use to pulverize back collection powder.
The 5th step, lyophilization:
Three kinds of powder after above-mentioned the 4th step pulverizing are respectively charged into lyophilizing in the freezer dryer, and freeze dried examination criteria is moisture＜10% of three kinds of powder, and take out back up to standard.
The 6th step, mixing:
The raw material that takes by weighing the three kind powder of the 5th step lyophilizing after up to standard by above-mentioned parts by weight of raw materials carries out mixing.
The 7th step, sterilization:
Powder behind the 6th step mixing was shone 1 minute under the Co60 ray.Perhaps the powder behind the mixing is packed in the band agitating device rustless steel container that can seal, powder charge weight≤rustless steel container volume half the, half that installs to container volume with powder is advisable; In rustless steel container, charge into the ozone gas of 20000～33000ppm again, stir, be full of the back sealing and stirred 30 minutes while filling.Adopt a kind of sterilization back in the dual mode to collect powder, packing warehouse-in, room temperature preservation.
The 8th step, making finished product:
Powder after the sterilization is processed capsule formulation or tablet form finished product by following mode;
Capsule formulation: the powder after the sterilization of the 7th step is incapsulated in the make-up machine, and capsule employing capacity is No. 1 capsule of 0.25 gram, and every net weight 0.25 gram after packing into is chosen the capsule of breakage, is made into capsule board or bottled product then.
Tablet: the requirement of making tablet by the pharmaceutical factory when being made into tablet adds the medical starch through sterilization of ormal weight; Tabletting, sugar coating, every weight 1g～2g, every gram contain above-mentioned powder 0.25g.
The 9th step, packing back warehouse-in, room temperature preservation.
The new drug of this treatment cardiovascular and cerebrovascular disease is a raw material with Hirudo, Radix Notoginseng, Pheretima; After processing through special preparation technology; Can preserve the active component of Hirudo to greatest extent, be beneficial to absorption, good effect; Has blood circulation promoting and blood stasis dispelling, the resultant effect of anticoagulant, blood pressure lowering, blood fat reducing, antiplatelet aggregation, thrombolytic.
The above is the specific embodiment of this invention; Above-mentioned not illustrating constitutes restriction to flesh and blood of the present invention; Under the those of ordinary skill of technical field after having read this description, can make an amendment or be out of shape the above-mentioned specific embodiment, and do not deviate from essence of the present invention and scope.
Claims (3)
1. a new drug of treating cardiovascular and cerebrovascular disease is characterized in that, it is processed by the raw material of following weight parts:
8～12 parts of Hirudo powder, 8～12 parts of Radix Notoginseng powder, 5～8 parts of Pheretima powder;
Described Hirudo powder is blood-eating hirudo powder, beautiful doctor trematodiasis powder, Hirudinaria manillensis powder, excellent stricture of vagina cattle trematodiasis powder, Hubei cattle trematodiasis powder or Nanjing cattle trematodiasis powder;
A kind of method for preparing that is used for the new drug of above-mentioned treatment cardiovascular and cerebrovascular disease is characterized in that, it is made up of following step:
The first step, selection check medical material:
Hirudo: must be that healthy live body or live body freezes article, antithrombin activity component content＞50A-TU/g, content of beary metal should satisfy the pharmacopeia requirement, total ash≤5.0%, acid-insoluble ash≤2.0%, extractum＞2.0%;
Radix Notoginseng: select root and the supporting root of Radix Notoginseng for use, its total moisture≤14.0%, total ash≤6.0%, acid-insoluble ash≤3.0%, ethanol-soluble extractives＞16.0%, Radix Notoginseng total arasaponins＞5.0%;
Pheretima: select LUMBRICUS or thin white silk used in ancient China Pheretima, require its total moisture≤12.0%, total ash≤10.0%, acid-insoluble ash≤5.0%, heavy metal≤1,000,000/30, extractum＞16.0%;
Second step, medical material are handled:
The live body Hirudo is cleaned up with clear water, and the Pheretima live body then will be cut clean earth open, and the official method detection level is pressed in the sampling of Hirudo, Pheretima and three kinds of raw materials of Radix Notoginseng, and it is for use to detect qualified back;
The 3rd step, cryotherapy:
Hirudo and Pheretima are put into refrigerated cylinder, the amount of putting into≤refrigerated cylinder volume half the, inwards charges into liquid nitrogen again, liquid nitrogen reaches four of refrigerated cylinder volume/three o'clock to be stopped to charge into, and keeps 20 minutes, treat Hirudo and Pheretima adfreezing after taking-up for use;
The 4th step, pulverizing:
Hirudo, Pheretima and the Radix Notoginseng dry product that will pass through the liquid nitrogen quick freezing are respectively charged in the super micron mill of band refrigerating plant, pulverize temperature and are controlled at below 4 ℃, are crushed to 1～10 micron, and it is for use to pulverize back collection powder;
The 5th step, lyophilization:
Above-mentioned three kinds of powder are respectively charged into the freezer dryer lyophilizing, detect moisture＜10% back of three kinds of powder and take out;
The 6th step, mixing:
Take by weighing mixing behind each raw material by above-mentioned parts by weight of raw materials;
The 7th step, sterilization:
Powder behind the 6th step mixing was shone 1 minute under the Co60 ray; Perhaps the powder behind the mixing is packed in the band agitating device rustless steel container that can seal; Half of powder charge weight≤rustless steel container volume; In rustless steel container, charge into the ozone gas of 20000～33000ppm again, stir, be full of the back sealing and stirred 30 minutes while filling; Collect powder then, packing warehouse-in, room temperature preservation;
The 8th step, making finished product:
Powder after the sterilization is processed capsule formulation or tablet form finished product by following mode;
Capsule formulation: the powder after the sterilization of the 7th step is incapsulated in the make-up machine, and capsule employing capacity is No. 1 capsule of 0.25 gram, and every net weight 0.25 gram after packing into is chosen the product of breakage, is made into capsule board or bottled product then;
Tablet: the medical starch of making the requirement adding ormal weight of tablet by the pharmaceutical factory through sterilization; Tabletting, sugar coating, every weight 1g～2g, every gram contain above-mentioned powder 0.25g;
The 9th step, packing back warehouse-in, room temperature preservation.
2. a kind of new drug of treating cardiovascular and cerebrovascular disease according to claim 1 is characterized in that the preferred version of its each parts by weight of raw materials is:
9～11 parts of Hirudo powder, 9～11 parts of Radix Notoginseng powder, 6～7 parts of Pheretima powder.
3. a kind of new drug of treating cardiovascular and cerebrovascular disease according to claim 1 is characterized in that the preferred plan of its each parts by weight of raw materials is:
10 parts of Hirudo powder, 10 parts of Radix Notoginseng powder, 7 parts of Pheretima powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103181993A CN102793734A (en) | 2012-09-01 | 2012-09-01 | Novel medicament for treating cardio-cerebrovascular diseases and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103181993A CN102793734A (en) | 2012-09-01 | 2012-09-01 | Novel medicament for treating cardio-cerebrovascular diseases and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102793734A true CN102793734A (en) | 2012-11-28 |
Family
ID=47193203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012103181993A Pending CN102793734A (en) | 2012-09-01 | 2012-09-01 | Novel medicament for treating cardio-cerebrovascular diseases and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102793734A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103230443A (en) * | 2013-04-23 | 2013-08-07 | 周术凯 | Traditional Chinese medical composition for treating hypertension |
| CN103735584A (en) * | 2014-01-21 | 2014-04-23 | 谢国清 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases |
| CN107714745A (en) * | 2017-10-30 | 2018-02-23 | 邱寿祥 | It is a kind of can with thrombolysis, promote blood circulation, the medicine pill of lipid-loweringing |
| CN107789596A (en) * | 2016-08-31 | 2018-03-13 | 浙江康恩贝制药股份有限公司 | A kind of Anshen Bunao granule preparing process |
| CN112826855A (en) * | 2021-01-04 | 2021-05-25 | 刘�文 | Traditional Chinese medicine and probiotic composite synergistic lipid-lowering thrombolytic preparation and preparation method thereof |
-
2012
- 2012-09-01 CN CN2012103181993A patent/CN102793734A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103230443A (en) * | 2013-04-23 | 2013-08-07 | 周术凯 | Traditional Chinese medical composition for treating hypertension |
| CN103230443B (en) * | 2013-04-23 | 2015-09-16 | 周术凯 | Treat hypertensive Chinese medicine composition |
| CN103735584A (en) * | 2014-01-21 | 2014-04-23 | 谢国清 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases |
| CN103735584B (en) * | 2014-01-21 | 2016-09-07 | 谢国清 | The Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease |
| CN107789596A (en) * | 2016-08-31 | 2018-03-13 | 浙江康恩贝制药股份有限公司 | A kind of Anshen Bunao granule preparing process |
| CN107714745A (en) * | 2017-10-30 | 2018-02-23 | 邱寿祥 | It is a kind of can with thrombolysis, promote blood circulation, the medicine pill of lipid-loweringing |
| CN112826855A (en) * | 2021-01-04 | 2021-05-25 | 刘�文 | Traditional Chinese medicine and probiotic composite synergistic lipid-lowering thrombolytic preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2367464C2 (en) | Composition for treating chronic venous insufficiencies, containing aqueous extract of red grape leaves and antiinflammatory agent | |
| CN102091203B (en) | External traditional Chinese medicine preparation for treating refractory wound and preparation method thereof | |
| CN101168042A (en) | Traditional Chinese medicine preparation for curing cardiovascular and cerebrovascular diseases and preparing method | |
| CN102793734A (en) | Novel medicament for treating cardio-cerebrovascular diseases and preparation method | |
| CN104784473A (en) | Earthworm protein health care product | |
| CN103083400A (en) | Drug for treating cardiovascular disease | |
| CN102861287A (en) | Chinese medicinal composition for treating damp-heat invasion blood stasis diabetic foot and preparation method thereof | |
| CN104435449B (en) | A kind of pharmaceutical composition of antiatherosclerosis and its application | |
| KR102127706B1 (en) | Preparation for improving blood circulation comprising mixed oriental medicinal extracts | |
| CN101879267B (en) | Compound tincture for treating foot helosis | |
| CN103800635A (en) | Medicinal and edible two-purpose composition for preventing and treating coronary heart disease and preparation method thereof | |
| CN104997890B (en) | A kind of Chinese materia medica preparation for treating fracture | |
| CN103860691A (en) | External pure traditional Chinese medicine preparation for treating burns and scalds | |
| CN106138831A (en) | A kind of Chinese medicine composition treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN102552410B (en) | Preparation method of medicine for treating hypertension disease | |
| CN102524763A (en) | Seabuckthorn oil soft capsules and preparation method thereof | |
| CN107854614B (en) | Powder for treating soft tissue injury and preparation method thereof | |
| CN102793723A (en) | Superfine grinding method for animal used as medicine | |
| CN104127706A (en) | Traditional Chinese medicinal preparation for holistically treating cardio-cerebrovascular diseases of old people, and preparation method thereof | |
| CN107929492A (en) | A kind of strong doctor's external preparation for treating abscess and preparation method thereof | |
| CN104547929B (en) | A kind of Chinese medicine and preparation method for treating apoplexy sequelae | |
| CN102526449B (en) | Drug combination for treating coronary heart diseases caused by myocardial ischemia | |
| KR102127726B1 (en) | Preparation for improving blood circulation comprising mixed oriental medicinal extracts | |
| CN101642536B (en) | Plaster for treating hyperosteogeny | |
| CN105194313A (en) | Traditional Chinese medicine treating paroxysmal atrial fibrillation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121128 |